Submit complete Phase-I CT report: CDSCO Panel Tells Biological E on Bivalent Typhoid and Paratyphoid A Conjugate Vaccine Dr. Divya Colin23 July 2024 6:00 PM ISTNew Delhi: Reviewing the interim Phase-I clinical trial report of Typhoid and Paratyphoid A Conjugate Vaccine Bivalent, the Subject Expert Committee...
CDCSO Declares 31 Formulations As Not of Standard Quality: Details Dr. Divya Colin22 July 2024 6:00 PM ISTNew Delhi: In its latest drug safety alert, the apex drug regulatory body, the Central Drug Standard Control Organisation (CDSCO), has flagged 31...
Conduct Phase III CT: CDSCO Panel Tells BDR Pharmaceuticals on Linaclotide Capsules Dr. Divya Colin21 July 2024 6:00 PM ISTNew Delhi: Granting a waiver of the bioequivalence (BE) study, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Submit data on prevalence and genetic polymorphism of disease: CDSCO Panel Tells Dr Reddy's Laboratories on Siponimod tablet Dr. Divya Colin20 July 2024 6:00 PM ISTNew Delhi:In response to the proposal presented by the drug major Dr Reddy's Laboratories to manufacture and market the neurodrug Siponimod tablets...
Dr Reddy's Laboratories Gets CDSCO Panel Nod To Study Rebamipide, Sodium Alginate Suspension Dr. Divya Colin19 July 2024 6:00 PM ISTNew Delhi: The drug major Dr Reddy's Laboratories has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Dr Reddy's Laboratories Gets CDSCO Panel Nod To Manufacture, Market Elobixibat Tablet Dr. Divya Colin18 July 2024 6:00 PM ISTNew Delhi: The drug major Dr Reddy's Laboratories has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
IT Department sends Rs 773 crore demand notice to Cipla Ruchika Sharma17 July 2024 4:37 PM ISTMumbai: Pharmaceutical giant Cipla has disclosed that it has received a demand notice amounting to Rs 773.44 crore from the Income Tax...
Cipla Gets CDSCO Panel Nod to Study Plazomicin Injection Dr. Divya Colin16 July 2024 6:00 PM ISTNew Delhi: The drug major Cipla has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Submit Separate Retrospective, Prospective Study data of subjects: CDSCO Panel Tells Takeda on Velaglucerase alfa study Dr. Divya Colin15 July 2024 6:00 PM ISTNew Delhi: Regarding the post-marketing surveillance study of the drug major Takeda Pharmaceutical's Velaglucerase alfa injection, the Subject Expert...
CDSCO Panel approves Novartis Healthcare for selective use of Secukinumab dose up to 300 mg Dr. Divya Colin14 July 2024 6:00 PM ISTNew Delhi: Reviewing the justification presented by the drug major Novartis Healthcare for the monoclonal antibody Secukinumab, the Subject Expert...
Intas Pharmaceuticals Gets CDSCO Panel Nod for Palatability Study of Temozolomide powder for oral suspension Dr. Divya Colin13 July 2024 6:00 PM ISTNew Delhi: The drug major Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Roche Products India gets CDSCO Panel Nod To study anti-cancer drug Pralsetinib Capsule Dr. Divya Colin12 July 2024 6:00 PM ISTNew Delhi: The drug major Roche Products India has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
